Also known as: 2-Ethoxyethanol, Acetate, Ektasolve EE acetate solvent, Ethoxyethyl acetate, 2-Ethoxyethylacetate, Ethylglycol acetate (+14 more)
CAS 111-15-9
Ethylene glycol monoethyl ether acetate (CAS 111-15-9) is a chemical substance with GHS signal word Danger; key hazard signal: H226; H360FD; H332; H312; H302. Key regulatory status: SVHC Candidate List, California Proposition 65, 7 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from ECHA CLP, EPA ToxValDB, EPA CPDat, AICIS, ECHA SVHC, CA Prop 65, ILO ICSC, OSHA.
Ethylene glycol monoethyl ether acetate is prohibited in EU cosmetics but has active industrial GHS classifications (H226, H360FD, H332, H312, H302).
CAS, identifiers, formula, and alternate names for the matched substance record.
Candidate List status and reason under the ECHA REACH SVHC program.
| Substance | Reason | Included |
|---|---|---|
| 2-ethoxyethyl acetate | Toxic for reproduction (Article 57c) | 20-Jun-2011 |
California OEHHA listing status and toxicity category.
| Chemical | Toxicity Type | Cancer | Developmental | Listed |
|---|---|---|---|---|
| - | developmental, male | No | Yes | - |
EU harmonized hazard classification, hazard statements, pictograms, and signal word.
| Hazard Class | H-Statements | Pictograms | Signal |
|---|---|---|---|
| Flam. Liq. 3; Repr. 1B; Acute Tox. 4 *; Acute Tox. 4 *; Acute Tox. 4 * | H226; H360FD; H332; H312; H302 | GHS02; GHS08; GHS07 | Danger |
International Chemical Safety Card hazard and exposure summary.
| Field | Value |
|---|---|
| Short-term Effects | The vapour is mildly irritating to the eyes. The substance may cause effects on the blood at high levels. This may result in lesions of blood cells and kidney impairment. The substance may cause effects on the central nervous system. Exposure far above the OEL could cause unconsciousness. |
| Long-term Effects | The substance defats the skin, which may cause dryness or cracking. The substance may have effects on the blood. This may result in lesions of blood cells, anaemia and kidney impairment. May cause toxicity to human reproduction or development. |
| Routes of Exposure | The substance can be absorbed into the body by inhalation of its vapour, through the skin and by ingestion. |
Occupational exposure limits from OSHA, NIOSH, and ACGIH rows.
| Agency | Metric | Value | ppm | mg/m3 | Skin |
|---|---|---|---|---|---|
| OSHA | TWA | 100 ppm (540 mg/m³) | 100 | 540 | Y |
| NIOSH | TWA | 0.5 ppm (2.7 mg/m³) | 0.5 | 2.7 | Y |
| ACGIH | TWA | 5 ppm [1981] | 5 | - | Y |
| CAL/OSHA | TWA | 5 ppm (27 mg/m³) | 5 | 27 | Y |
| NIOSH | IDLH | 500 ppm | 500 | - | - |
Industrial and product-use categories associated with this substance.
Inventory, screening, and regulatory list matches from public chemical databases.
| List | Keyword | Source |
|---|---|---|
| Cons electronics mech appliances and machinery; Europe | Danish Environmental Protection Agency | Danish EPA |
| consumer_product | P&G | Proctor & Gamble |
| CEDI | FDA | United States Food and Drug Administration (FDA) |
| Indirect additives food contact (10/2018) | FDA | United States Food and Drug Administration (FDA) |
| OEHHA Proposition 65 (3/2019) | STATE OF CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY | OEHHA Proposition 65 List |
| OEHHA Proposition 65 (1/2023) | California Office of Environmental Health Hazard Assessment | OEHHA Proposition 65 List |
| air; Cons electronics mech appliances and machinery; detected; emissions; Europe | Danish Environmental Protection Agency | Danish EPA |
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| =6.5 | mg/m3 | BMCL (10 HEC) | inhalation | Rat | ToxValDB_PPRTV_(CPHEA) |
| =356 | mg/kg bw/day | BMDL (1SD ADJ) | oral | Mouse | ToxValDB_PPRTV_(CPHEA) |
| ABinhalation=1400; oral=1100 | ug/day | California Proposition 65 MADL | - | - | California Proposition 65 |
| ABinhalation=1400; oral=1100 | ug/day | California Proposition 65 MADL | - | - | California Proposition 65 |
| ABinhalation=1400; oral=1100 | ug/day | California Proposition 65 MADL | - | - | California Proposition 65 |
| ABinhalation=1400; oral=1100 | ug/day | California Proposition 65 MADL | - | - | California Proposition 65 |
| ABdevelopmental, male | listing type | California Proposition 65 listing | - | - | California Proposition 65 |
| ABdevelopmental, male | listing type | California Proposition 65 listing | - | - | California Proposition 65 |
| ABdevelopmental, male | listing type | California Proposition 65 listing | - | - | California Proposition 65 |
| ABdevelopmental, male | listing type | California Proposition 65 listing | - | - | California Proposition 65 |
| 15 | unitless | Draize rabbit irritation score | Ocular | Rabbit | NTP_ICE_eye_irritation |
| 15 | unitless | Draize rabbit irritation score | Ocular | Rabbit | NTP_ICE_eye_irritation |
| 15 | unitless | Draize rabbit irritation score | Ocular | Rabbit | NTP_ICE_eye_irritation |
| 15 | unitless | Draize rabbit irritation score | Ocular | Rabbit | NTP_ICE_eye_irritation |
| 3 | unitless | EPA Classification | Ocular | Rabbit | NTP_ICE_eye_irritation |
| 3 | unitless | EPA Classification | Ocular | Rabbit | NTP_ICE_eye_irritation |
| 3 | unitless | EPA Classification | Ocular | Rabbit | NTP_ICE_eye_irritation |
| 3 | unitless | EPA Classification | Ocular | Rabbit | NTP_ICE_eye_irritation |
| DG1O0Z7390 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| DG1O0Z7390 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| DG1O0Z7390 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| DG1O0Z7390 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 2 | unitless | GHS Classification | Ocular | Rabbit | NTP_ICE_eye_irritation |
| 2 | unitless | GHS Classification | Ocular | Rabbit | NTP_ICE_eye_irritation |
| 2 | unitless | GHS Classification | Ocular | Rabbit | NTP_ICE_eye_irritation |
| 2 | unitless | GHS Classification | Ocular | Rabbit | NTP_ICE_eye_irritation |
| 0.2 | %/sec | Intensity | Ocular | - | NTP_ICE_eye_irritation |
| 0.2 | %/sec | Intensity | Ocular | - | NTP_ICE_eye_irritation |
| 0.2 | %/sec | Intensity | Ocular | - | NTP_ICE_eye_irritation |
| 0.2 | %/sec | Intensity | Ocular | - | NTP_ICE_eye_irritation |
| >8.1029 | mg/L | LC50 | Inhalation | - | NTP_ICE_acute_inhalation |
| 12.1 | mg/L | LC50 | Inhalation | - | NTP_ICE_acute_inhalation |
| =2700 | mg/kg bw | LD50 | oral | Rat | NTP_ICE_acute_oral |
| =2900 | mg/kg bw | LD50 | oral | Rat (Female) | NTP_ICE_acute_oral |
| =3900 | mg/kg bw | LD50 | oral | Rat (Male) | NTP_ICE_acute_oral |
| =5100 | mg/kg bw | LD50 | oral | Rat | NTP_ICE_acute_oral |
| =91890.1 | mg/m3 | LEL | inhalation | Human | ToxValDB_DOE_Protective_Action_Criteria |
| =135.133 | mg/m3 | LOAEL | inhalation | Rabbit | ToxValDB_Cal_OEHHA_REL_derivations |
| - | s | Lag time | Ocular | - | NTP_ICE_eye_irritation |
| - | s | Lag time | Ocular | - | NTP_ICE_eye_irritation |
| - | s | Lag time | Ocular | - | NTP_ICE_eye_irritation |
| - | s | Lag time | Ocular | - | NTP_ICE_eye_irritation |
| - | unitless | Model Score | - | - | NTP_ICE_endocrine |
| 37 | % | Plateau level | Ocular | - | NTP_ICE_eye_irritation |
| 37 | % | Plateau level | Ocular | - | NTP_ICE_eye_irritation |
| 37 | % | Plateau level | Ocular | - | NTP_ICE_eye_irritation |
| 37 | % | Plateau level | Ocular | - | NTP_ICE_eye_irritation |
| =0.3 | mg/m3 | RfC | inhalation | Human | ToxValDB_EPA_HWIR |
| =0.06 | mg/m3 | RfC (provisional) | inhalation | Human | ToxValDB_PPRTV_(CPHEA) |
| =0.1 | mg/kg bw/day | RfD (provisional) | oral | Human | ToxValDB_PPRTV_(CPHEA) |
Showing 50 of 51 studies
Australian industrial chemicals inventory status and applicable conditions.
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
Ethylene glycol monoethyl ether acetate (CAS 111-15-9) is classified under EU CLP Annex VI as Flam. Liq. 3; Repr. 1B; Acute Tox. 4 *; Acute Tox. 4 *; Acute Tox. 4 * with signal word Danger. Hazard statements: H226; H360FD; H332; H312; H302. Source: EU CLP Annex VI (ECHA).
Ethylene glycol monoethyl ether acetate has 51 NOAEL studies in the database. The lowest reported value is 6.5 mg/m3 via inhalation in Rat. Source: ToxValDB_PPRTV_(CPHEA).
Ethylene glycol monoethyl ether acetate appears on 7 regulatory/inventory lists including Cons electronics mech appliances and machinery; Europe, consumer_product, CEDI, and 4 more. Source: EPA CPDat.
Yes, Ethylene glycol monoethyl ether acetate is listed under California Proposition 65 for developmental, male. Source: California OEHHA Proposition 65.
Yes, Ethylene glycol monoethyl ether acetate is listed on the ECHA REACH Candidate List as a Substance of Very High Concern. Reason: Toxic for reproduction (Article 57c). Source: ECHA SVHC Candidate List.
Occupational exposure limits for Ethylene glycol monoethyl ether acetate are set by OSHA, NIOSH, ACGIH. 5 limit values from official agencies are documented in the database. Source: OSHA, NIOSH, ACGIH.
Yes, Ethylene glycol monoethyl ether acetate is also indexed as a cosmetic ingredient under the name Ethoxyethanol Acetate. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from ECHA CLP Annex VI, EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, ECHA SVHC Candidate List, California Proposition 65, ILO/WHO ICSC, OSHA/NIOSH/ACGIH, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
Ethylene glycol monoethyl ether acetate is prohibited in EU cosmetics but has active industrial GHS classifications (H226, H360FD, H332, H312, H302).
Ethylene glycol monoethyl ether acetate also appears in cosmetics, pharmaceutical databases.